Cysteamine Bitartrate
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mitochondrial Diseases
Conditions
Mitochondrial Diseases
Trial Timeline
May 19, 2015 → Mar 6, 2017
NCT ID
NCT02473445About Cysteamine Bitartrate
Cysteamine Bitartrate is a phase 2 stage product being developed by Amgen for Mitochondrial Diseases. The current trial status is terminated. This product is registered under clinical trial identifier NCT02473445. Target conditions include Mitochondrial Diseases.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02473445 | Phase 2 | Terminated |
| NCT02023866 | Phase 2 | Completed |
Competing Products
13 competing products in Mitochondrial Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| REN001 | OnKure Therapeutics | Phase 1 | 25 |
| Mavodelpar + Placebo | OnKure Therapeutics | Phase 2 | 44 |
| REN001 | OnKure Therapeutics | Phase 2/3 | 57 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 2 | 52 |
| Omaveloxolone capsules, 2.5 mg + omaveloxolone capsules, 5 mg + omaveloxolone capsules, 10 mg + Placebo capsules + omaveloxolone capsules, 20 mg + omaveloxolone capsules, 40 mg + omaveloxolone capsules, 80 mg + omaveloxolone capsules, 160 mg | AbbVie | Phase 2 | 52 |
| Cysteamine Bitartrate | Amgen | Phase 2 | 51 |
| Vatiquinone | PTC Therapeutics | Phase 2/3 | 62 |
| EPI-743 | PTC Therapeutics | Pre-clinical | 20 |
| RG2133 (2',3',5'-tri-O-acetyluridine) | Repligen | Phase 1 | 30 |
| Vatiquinone | PTC Therapeutics | Pre-clinical | 20 |
| Vatiquinone | PTC Therapeutics | Phase 3 | 74 |
| Oral administration of 100 mg KH176 twice daily | Certara | Phase 2 | 47 |
| Sonlicromanol + Placebo | Certara | Phase 2 | 47 |